BioRestorative Therapies Regains Compliance with Nasdaq Itemizing Rule 5250(c)(1); Stories First Quarter 2024 Monetary Outcomes

– Important YoY enchancment in working efficiency –

– Ends Q1-2024 with $16.4 million money, money equivalents, and marketable securities –

MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Firm”) (NASDAQ:BRTX), a medical stage firm targeted on stem cell-based therapies, introduced that it has obtained discover from the Nasdaq Inventory Market that it has regained compliance with Nasdaq Itemizing Rule 5250(c)(1) in reference to the submitting of its Quarterly Report on Kind 10-Q for the fiscal quarter ended March 31, 2024 with the Securities and Trade Fee.

Abstract First Quarter 2024 Outcomes

For the quarter ended March 31, 2024, the Firm had a loss from operations of $4.1 million, a 29% enchancment from the $5.8 million loss from operations for the comparable interval of 2023. The Firm’s web loss for the 2024 first quarter was $2.2 million, or $0.33 per share, in comparison with a web lack of $7.2 million, or $1.93 per share, for the comparable interval in 2023.

Money utilized in working actions within the first quarter of 2024 was $2.3 million, in comparison with $2.4 million in Q1-2023.

The Firm ended the primary quarter in a robust monetary place, with money, money equivalents, and investments held in marketable securities of $16.4 million as of March 31, 2024.

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic merchandise utilizing cell and tissue protocols, primarily involving grownup stem cells. As described under, our two core medical improvement packages relate to the remedy of disc/backbone illness and metabolic issues, and we’ve additionally just lately begun providing BioCosmeceutical merchandise:

• Disc/Backbone Program (brtxDISC^™): Our lead cell remedy candidate, BRTX-100, is a product formulated from autologous (or an individual’s personal) cultured mesenchymal stem cells collected from the affected person’s bone marrow. We intend that the product will likely be used for the non-surgical remedy of painful lumbosacral disc issues or as a complementary therapeutic to a surgical process. The BRTX-100 manufacturing course of makes use of proprietary expertise and entails gathering a affected person’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient process, BRTX-100 is to be injected by a doctor into the affected person’s broken disc. The remedy is meant for sufferers whose ache has not been alleviated by non-invasive procedures and who probably face the prospect of surgical procedure. We’ve got commenced a Section 2 medical trial utilizing BRTX-100 to deal with power decrease again ache arising from degenerative disc illness.

• Metabolic Program (ThermoStem^®): We’re growing cell-based remedy candidates to focus on weight problems and metabolic issues utilizing brown adipose (fats) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), in addition to exosomes secreted by BADSC. BAT is meant to imitate naturally occurring brown adipose depots that regulate metabolic homeostasis in people. Preliminary preclinical analysis signifies that elevated quantities of brown fats in animals could also be liable for extra caloric burning in addition to decreased glucose and lipid ranges. Researchers have discovered that individuals with greater ranges of brown fats might have a decreased threat for weight problems and diabetes. BADSC secreted exosomes might also influence weight reduction.

• BioCosmeceuticals: We function a industrial BioCosmeceutical platform. Our present industrial product, formulated and manufactured utilizing our cGMP ISO-7 licensed clear room, is a cell-based secretome containing exosomes, proteins and progress elements. This proprietary biologic serum has been particularly engineered by us to cut back the looks of tremendous strains and wrinkles and convey forth different areas of beauty effectiveness. Transferring ahead, we additionally intend to discover the potential of increasing our industrial providing to incorporate a broader household of cell-based biologic aesthetic merchandise and therapeutics by way of Investigational New Drug (IND)-enabling research, with the purpose of pioneering U.S. Meals and Drug Administration (FDA) approvals within the rising BioCosmeceuticals house.

Ahead-Trying Statements

This press launch comprises “forward-looking statements” throughout the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended, and such forward-looking statements are made pursuant to the protected harbor provisions of the Personal Securities Litigation Reform Act of 1995. You’re cautioned that such statements are topic to a large number of dangers and uncertainties that would trigger future circumstances, occasions or outcomes to vary materially from these projected within the forward-looking statements on account of varied elements and different dangers, together with, with out limitation, these set forth within the Firm’s newest Kind 10-Ok, as amended, filed with the Securities and Trade Fee. You must contemplate these elements in evaluating the forward-looking statements included herein, and never place undue reliance on such statements. The forward-looking statements on this launch are made as of the date hereof and the Firm undertakes no obligation to replace such statements.

CONTACT:

Electronic mail: [email protected]